Supplementary Figure S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial

Read full text Summarise with VIRAT
Authors: Susanne A. Gatz, Pablo Berlanga, Gwénaël Le Teuff, Ivan Valiev, Amaury Leruste, Nicolás André, Dominique Bluteau, Nadège Corradini, Jonathan Rubino, Fabienne Thomas, Souad Nebchi, Eleni Karamouza
+27 more Jeanne Petit, Estelle Thébaud, Alba Rubio-San-Simón, Natasha K.A. van Eijkelenburg, Lynley V. Marshall, Sandra Raimbault, Adela Canete, Stephane Ducassou, Guy Makin, Michela Casanova, Émilie De Carli, Arnaud Petit, Melis Cardon, Ludovic Lacroix, Gaëlle Pierron, Gudrun Schleiermacher, Michael J.F. Hubank, Aroa Soriano, Karin P.S. Langenberg, David Castel, Tiphaine Adam-de Beaumais, Xavier Paolettí, Pradeep B. Lukka, Richard Baldry, Peter G. S. Mortimer, Sergey I. Nikolaev, Birgit Geoerger
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Comparison of Homologous Recombination Deficiency (HRD) Scores and Tumor Mutational Burden (TMB) Between Treatment Responders and Non-Responders.

Fields of Study & Subjects

PARP inhibition in cancer therapy BRCA gene mutations in cancer Acute Lymphoblastic Leukemia research

Publication details

Publication date
1 April 2026
Language
EN